Molecules against Target MAPK14
![]() |
| ||||||||||
![]() |
| ||||||||||
![]() |
| ||||||||||
![]() |
| ||||||||||
![]() |
| ||||||||||
![]() |
| ||||||||||
![]() |
| ||||||||||
![]() |
| ||||||||||
![]() |
| ||||||||||
![]() |
| ||||||||||
![]() |
| ||||||||||
![]() |
| ||||||||||
![]() |
| ||||||||||
![]() |
| ||||||||||
![]() |
| ||||||||||
![]() |
| ||||||||||
![]() |
| ||||||||||
![]() |
| ||||||||||
![]() |
| ||||||||||
![]() |
|
Note: If you'd like to learn how our AI-powered BDE-Chem can help design therapeutic molecules against the MAPK14 target, that break through the existing patents, at a cost 90% lower than traditional approaches, please feel free to contact us at BD@silexon.ai
Molecules for More Common Targets
ABCB1 | ABCG2 | ACE2 | AHR | AKT1 | ALK | AR | ATM | BAX | BCL2 | BCL2L1 | BRAF | BRCA1 | CASP3 | CASP9 | CCL5 | CCND1 | CD274 | CD4 | CDKN1A | CXCL8 | CXCR4 | DNMT1 | EGF | EGFR | EP300 | ERBB2 | ESR1 | EZH2 | FN1 | FOXO3 | HDAC9 | HGF | HMGB1 | HSP90AA1 | HSPA5 | IDO1 | IGF1 | IGF1R | IL17A | IL6 | INS | JUN | KRAS | MAPK1 | MAPK14 | MAPK3 | MAPK8 | MAPT | MCL1 | MMP9 | MTOR | MYC | NFE2L2 | NLRP3 | NOTCH1 | PARP1 | PCNA | PDCD1 | PLK1 | PRKAA1 | PRKAA2 | PTEN | PTGS2 | PTK2 | RELA | SIRT1 | SRC | STAT1 | STAT3 | STAT5A | TERT | TLR4 | TNF | TP53 | TXN | VEGFA | YAP1